NCT05295940CompletedPhase 1
A Study of LY3841136 in Healthy and Overweight Participants
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3841136 in Healthy and Overweight Participants
Source: ClinicalTrials.gov · Last updated 1 Apr 2024
Brief summary (registry, in English)
The main purpose of this study is to evaluate the safety and tolerability of LY3841136 in healthy and overweight participants. Blood tests will be performed to check how much LY3841136 gets into the bloodstream and how long it takes the body to eliminate it. This is a 2-part study and may last up to 14 and 28 weeks for each participant and may include 7 and 19 visits in parts A and B, respectively.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 148 (actual)
- First submitted
- 24 Mar 2022
- Start date
- 30 Mar 2022
- Primary completion date
- 25 Jan 2024
- Lead sponsor
- Eli Lilly and Company
- Diseases
- Obesity
- NCT number
- NCT05295940
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 148
- From 30 Mar 2022 to the primary completion date, 25 Jan 2024
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Have known allergies to related compounds of LY3841136 or any components of the formulation
- Have a history of significant atopy (severe or multiple allergic manifestations), or clinically significant multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions
- Have been diagnosed with Type 1 or Type 2 diabetes mellitus
- Have a history of chronic medical conditions involving the heart, liver, or kidneys
Other
- Are women who are lactating
Who the study is looking for
- Male participants who agree to use highly effective/effective methods of contraception and female participants not of childbearing potential
- Have had a stable weight for the last 3 months
- Have a body mass index (BMI) in the range of 18.5 to 32 kilogram per square meter (kg/m²), both inclusive (in Part A) or a BMI in the range of 27 to 40 kg/m², both inclusive (in Part B)
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (3)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fortrea Clinical Research Unit Coordinator of this site? Confirm its status | Dallas | United States | Unknown status |
| Fortrea Clinical Research Unit Coordinator of this site? Confirm its status | Daytona Beach | United States | Unknown status |
| Fortrea Clinical Research Unit Coordinator of this site? Confirm its status | Madison | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.